ReviewNature reviews. Urology2023
Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade.
Review in Nature reviews. Urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.Journal for immunotherapy of cancer · 2026Guideline
- Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses.Journal for immunotherapy of cancer · 2026Trial
- Adjuvant immunotherapy for renal cell carcinoma: understanding complexity, embracing uncertainty, making a difference.Nature reviews. Urology · 2026Article
- ASO Author Reflections: Risk-Adapted Use of Adjuvant Systemic Therapy in Real-World Kidney Cancer Care.Annals of surgical oncology · 2026Article
- Risk-Adapted Use of Adjuvant Systemic Therapy After Nephrectomy for Renal Cell Carcinoma: A Population-Based Study in the Post-approval Era.Annals of surgical oncology · 2026Article
- Bioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Trends and etiological profile of kidney cancer in China from 1990 to 2023: an analysis of modifiable risk factors and prevention implications using GBD 2023 estimates.International journal of clinical oncology · 2026Review
- Epigenetic activation of VEGFA by SMARCD1 mediates tumor progression and bevacizumab resistance in clear cell renal cell carcinoma.BMC cancer · 2026Article
- Adjuvant therapy in chromophobe renal cell carcinoma: current evidence and unmet needs.Frontiers in oncology · 2026Review
- ACOX2 destabilizes the MRE11-RAD50-NBS1 complex and boosts anticancer immunity via the cGAS-STING pathway in clear cell renal cell carcinoma.Molecular cancer · 2025Article
- Article
- Molecular imaging of renal cell carcinomas: ready for prime time.Nature reviews. Urology · 2025Review
- Adjuvant pembrolizumab following kidney cancer surgery A novel patient decision aid to facilitate shared decision-making.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Role of fructose in renal cell carcinoma progression.Discover oncology · 2025Article
- Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?Biomedicines · 2025Review
- GXYLT2: an emerging therapeutic target and predictive biomarker for anti-PD-1 efficacy in clear cell renal cell carcinoma.Genes and immunity · 2025Article
- Global spatio-temporal evolution and health inequalities in high BMI-associated kidney cancer burden from 1990 to 2021 and burden prediction to 2040.Frontiers in oncology · 2025Article
- Dynamic Changes in Serum Immunoglobulin G Predict Clinical Response and Prognosis in Metastatic Clear-cell Renal Cell Carcinoma.European urology open science · 2024Article
- Kidney Cancer Research Highlights from ASCO-GU 2024 Meeting.Kidney cancer journal : official journal of the Kidney Cancer Association · 2024Article
- Prognostic Value and Immunological Role of POP7 in Clear Cell Renal Cell Carcinoma.Pharmacogenomics and personalized medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Localized renal cell carcinoma (RCC) is primarily managed with nephrectomy, which is performed with curative intent. However, disease recurs in ~20% of patients. Treatment with adjuvant therapies is used after surgery with the intention of curing additional patients by disrupting the establishment, maturation or survival of micrometastases, processes collectively referred to as the metastatic cascade. Immune checkpoint inhibitors and vascular endothelial growth factor receptor (VEGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown efficacy in the treatment of metastatic RCC, increasing the interest in the utility of these agents in the adjuvant setting. Pembrolizumab, an inhibitor of the immune checkpoint PD1, is now approved by the FDA and is under review by European regulatory agencies for the adjuvant treatment of patients with localized resected clear cell RCC based on the results of the KEYNOTE-564 trial. However, the optimal use of immunotherapy and VEGFR-targeting TKIs for adjuvant treatment of RCC is not completely understood. These agents disrupt the metastatic cascade at multiple steps, providing biological rationale for further investigating the applications of these therapeutics in the adjuvant setting. Clinical trials to evaluate adjuvant therapeutics in RCC are ongoing, and clinical considerations must guide the practical use of immunotherapy and TKI agents for the adjuvant treatment of localized resected RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.